Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
RESEARCH TOOLSreports
Holding ELVN?
Track your performance easily
ELVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.90 - $30.03
Previous Close$22.47
Volume395.24K
Average Volume (3M)260.46K
Market Cap
$1.12B
Enterprise Value$825.58M
Total Cash (Recent Filing)$291.83M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 13, 2025EPS Estimate
-$0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding48,859,166
10 Day Avg. Volume189,427
30 Day Avg. Volume260,457
Standard Deviation0.29
R-Squared0.03
Alpha-0.00124
Financial Highlights & Ratios
Price to Book (P/B)3.81
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-22.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.96
Forecast
1Y Price Target
$38.67Price Target Upside72.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Enliven Therapeutics News
PremiumCompany Announcements
Enliven Therapeutics Reports Q3 Results and Clinical Progress
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageEnliven's CML drug remains ahead of peers, with better data and a differentiated mechanism of action to capture earlier line patients.
Drug DevelopmentELVN-001 is a next-generation BCR-ABL TKI which is differentiated in its selectivity, offering a wider therapeutic index, better safety/tolerability, and improved efficacy, especially against resistant mutations.
Market PotentialDemand for targeted therapies in large oncology indications remains high, and ELVN-001 has the potential to disrupt the large CML TKI market, which exceeded $6B in sales in 2021.
Bears Say
Drug SwitchingGreater than 35% of patients on Gleevec come off after 1.5 years, indicating drug switching may occur more frequently and leave patients without viable options sooner than expected.
Market CompetitionTERN-701 is seen as a direct competitor to ELVN-001, especially given its positive data in post-Scemblix treated patients.
Speculative RiskThe analysis indicates a speculative risk associated with the stock, suggesting a higher level of uncertainty for investors.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $10.90 and its highest was $30.03 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Currently, no data Available
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 81 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.497 by $0.017.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -$0.51.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 48,859,165 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.497. Following the earnings report the stock price went down -3.411%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Among the largest hedge funds holding Enliven Therapeutics’s share is Fairmount Funds Management Llc. It holds Enliven Therapeutics’s shares valued at 82M.
---
Enliven Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.67 (72.10% Upside)
$38.67 (72.10% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 916.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.33%
12-Months-Change
Fundamentals
Return on Equity
-30.98%
Trailing 12-Months
Asset Growth
11.45%
Trailing 12-Months
Company Description
Enliven Therapeutics
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
---
ELVN Stock 12 Month Forecast
Average Price Target
$38.67
▲(72.10% Upside)
Technical Analysis
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+28.39%
reiterated a buy rating 13 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +28.39% per trade.
---